What are the main factors affecting the demonstration of cost-effectiveness of respiratory sincitial virus vacunes for adults above 60 years of age - tlooto, The Most Powerful AcademicGPT

Cost-effectiveness of RSV vaccines for adults ≥60 hinges on disease burden, vaccine efficacy, costs, uptake, modeling, and implementation factors. - tlooto, AI-Powered Assistant for Academic and Research